EMEA-002691-PIP02-20

Table of contents

Key facts

Invented name
Beovu
Active substance
Brolucizumab
Therapeutic area
Ophthalmology
Decision number
P/0408/2020
PIP number
EMEA-002691-PIP02-20
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of diabetic retinopathy
Route(s) of administration
Intravitreal use
Contact for public enquiries
Novartis Europharm Limited

E-mail: paediatric.enquiries@novartis.com
Tel. +41 613246715

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating